MA24704A1 - Formulations nouvelles de paroxetine et procede pour leur preparation - Google Patents

Formulations nouvelles de paroxetine et procede pour leur preparation

Info

Publication number
MA24704A1
MA24704A1 MA25357A MA25357A MA24704A1 MA 24704 A1 MA24704 A1 MA 24704A1 MA 25357 A MA25357 A MA 25357A MA 25357 A MA25357 A MA 25357A MA 24704 A1 MA24704 A1 MA 24704A1
Authority
MA
Morocco
Prior art keywords
preparation
formulations
novel
paroxetine
paroxetine formulations
Prior art date
Application number
MA25357A
Other languages
English (en)
French (fr)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA24704A1 publication Critical patent/MA24704A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25357A 1997-11-21 1998-11-19 Formulations nouvelles de paroxetine et procede pour leur preparation MA24704A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation

Publications (1)

Publication Number Publication Date
MA24704A1 true MA24704A1 (fr) 1999-07-01

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25357A MA24704A1 (fr) 1997-11-21 1998-11-19 Formulations nouvelles de paroxetine et procede pour leur preparation

Country Status (24)

Country Link
EP (1) EP1033986A1 (es)
JP (1) JP2001523718A (es)
KR (1) KR20010032320A (es)
CN (1) CN1279608A (es)
AP (1) AP2000001821A0 (es)
AR (1) AR015485A1 (es)
AU (1) AU1168099A (es)
BG (1) BG104527A (es)
BR (1) BR9814220A (es)
CO (1) CO4970832A1 (es)
DZ (1) DZ2658A1 (es)
EA (1) EA200000552A1 (es)
GB (1) GB9724544D0 (es)
HU (1) HUP0100580A3 (es)
IL (1) IL136106A0 (es)
MA (1) MA24704A1 (es)
NO (1) NO20002590L (es)
OA (1) OA11385A (es)
PE (1) PE20000381A1 (es)
PL (1) PL340555A1 (es)
SK (1) SK7342000A3 (es)
TR (1) TR200001423T2 (es)
WO (1) WO1999026625A1 (es)
ZA (1) ZA9810637B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (en) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
WO2001002393A1 (en) 1999-07-01 2001-01-11 Italfarmaco S.P.A. Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
ES2294197T3 (es) * 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
HUP0000960A3 (en) * 1997-01-15 2001-04-28 Smithkline Beecham Plc Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
BG104527A (en) 2001-04-30
AU1168099A (en) 1999-06-15
OA11385A (en) 2004-01-27
ZA9810637B (en) 2000-05-22
DZ2658A1 (fr) 2003-03-22
BR9814220A (pt) 2001-12-26
EP1033986A1 (en) 2000-09-13
HUP0100580A2 (hu) 2002-04-29
NO20002590D0 (no) 2000-05-19
PL340555A1 (en) 2001-02-12
PE20000381A1 (es) 2000-05-07
NO20002590L (no) 2000-07-19
EA200000552A1 (ru) 2000-10-30
TR200001423T2 (tr) 2000-10-23
JP2001523718A (ja) 2001-11-27
SK7342000A3 (en) 2000-12-11
CN1279608A (zh) 2001-01-10
CO4970832A1 (es) 2000-11-07
IL136106A0 (en) 2001-05-20
WO1999026625A1 (en) 1999-06-03
HUP0100580A3 (en) 2002-05-28
GB9724544D0 (en) 1998-01-21
AR015485A1 (es) 2001-05-02
KR20010032320A (ko) 2001-04-16
AP2000001821A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98156A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procede pour leur preparation
MA26702A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2364030A1 (fr) Compositions pharmaceutiques a base d'anthocyanidines et procede pour leur preparation
DZ2666A1 (fr) Dérivés d'acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
TNSN96107A1 (fr) Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant
DZ2410A1 (fr) Dérivés d'acide arylsulfonylaminohydroxamique procédé pour leur préparation et compositions pharmaceutiques
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26733A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
MA29871B1 (fr) Composition pharmaceutique concue pour ameliorer la fonction cognitive
FR2378523A1 (fr) Medicament pour le traitement de l'acne
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.